Recent Updates
Recently added Catalysts

Zolpidem or placebo- Hypnotic drug given for sleep disorders

Phase 1

Obesity | Small molecule | Metabolic |GSK plc|Last Updated: Jun 20, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment49

FDA Designations

No designations recorded

Clinical trial landscape

Zolpidem or placebo- Hypnotic drug given for sleep disorders · 1 trial · 1 indication

Phase 1 1
NCT00976105Effects of Repeat Dosing of GSK1521498Obesity
COMPLETED49 Analytics
PHASE1COMPLETED
Effects of Repeat Dosing of GSK1521498
ObesityUnlock trial analytics

Study Endpoints

Primary Endpoints

Safety and tolerability: adverse events, blood pressure, heart rate, ECG, clinical chemistry, heamatology, urinalysis, change in reaction times, change in mood scales
During 10 days of repeat dosing
Obtain benchmarking data on the cognitive and mood changes induced by a single dose of up to 10mg zolpidem
Single occasion

Secondary Endpoints

Assess accumulation, dose proportionality and pharmacokinetics of GSK1521498: AUC (0-24), Cmax, tmax, tlag (Dose 1 only), t1/2 (Dose 10 only), trough plasma concentrations on Day 5, 7, 8, 9 and 10
On Day 1 and/or following 10 days of repeat dosing and trough samples on Day 5, 7, 8, 9 and 10
PK/PD relationships: cognitive and mood changes, pressure pain threshold and tolerance, heat pain threshold
During 10 days of reapeat dosing
Assess effects on body weight, fat mass, eating behaviour and personality traits: Bodyweight and BMI, Fat mass (ECHO-MRI), food ingested and energy intake, eating behaviour and persoality scales: Y-BOC-BE, BE, TFEQ and BIS
Screening, or Day -1 and Day 10
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part A: Zolpidem or placeboACTIVE_COMPARATORThis part is designed to examine the acute effects of up to 10mg of a known hypnotic sedative drug (Zolpidem) on cognitive and mood changes sensitve to sedation and tiredess.
Part B: GSK1521498 or placeboEXPERIMENTALAt least 15 hours after Part A is completed subjects will enter Part B of the study.

Interventions

NameTypeDescription
Zolpidem or placebo - Hypnotic drug given for sleep disordersDRUGThe information gathered from Part A will be used as a benchmark against which any effects of GSK1521498 can be assessed in Part B.
GSK1521498 or placeboDRUGThe first group will start at a low dose (10 mg GSK1521498 or placebo) for 10 days. The study team will then assess the data gathered from the first cohort and will select the dose that the next cohort will receive for 10 days. There will be up to 4 cohorts.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 60 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy as determined by a responsible and experienced physician * Non smoking male or female between 18 and 60 years of age inclusive * A female subject of child-bearing potential must use a contraception method listed in the protocol prior to the start of dosing until at lea...

Countries:United Kingdom
Unlock Eligibility Criteria